Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Proto Labs IncPRLB · Entity 4553 | President and CEO | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Proto Labs Inc
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,579 |
Reported balance
After 2025-02-25 transaction · row 1
1 source rowRow 1 · 2025-02-25 · Grant · Acquired 18,935 · Balance 108,579 F1: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.61 · Expires 2035-02-25 | Direct | 33,986 |
Reported balance
After 2025-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-25 · Grant · Acquired 33,986 · Balance 33,986 F2: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
F2: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2017 Filed Dec 13, 2017 22:09 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $36.41 | $0.00 |
DisclosureSEC source: 0001437749-17-020657 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:09 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 4,000 | $94.79 | $379,148.00 |
DisclosureSEC source: 0001437749-17-020657 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F2 · price: Reflects the weighted average price of 4,000 shares of common stock of Proto Labs, Inc. sold by the reporting person on December 11, 2017 with sale prices ranging from $94.50 to $95.45 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:09 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 4,000 | $36.41 | $145,640.00 |
DisclosureSEC source: 0001437749-17-020657 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,891 | $0.00 Strike: $57.88 | $0.00 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · derivative · entry 6 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,564 Underlying: Common Stock · 1,891 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning on February 13, 2017. Read SEC document |
| October 26, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 1,891 | $85.90 | $162,432.55 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · nonDerivative · entry 4 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F3 · price: Reflects the weighted average price of 1,891 shares of common stock of Proto Labs, Inc. sold by the reporting person on October 26, 2017 with sale prices ranging from $85.45 to $86.25 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 26, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 1,891 | $57.88 | $109,451.08 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · nonDerivative · entry 3 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $36.41 | $0.00 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · derivative · entry 5 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning on December 11, 2013. Read SEC document |
| September 29, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 4,000 | $80.00 | $320,011.60 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F2 · price: Reflects the weighted average price of 4,000 shares of common stock of Proto Labs, Inc. sold by the reporting person on September 29, 2017 with sale prices ranging from $80.00 to $80.10 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 29, 2017 Filed Nov 3, 2017 19:50 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 4,000 | $36.41 | $145,640.00 |
DisclosureSEC source: 0001437749-17-018261 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 741 | $0.00 Strike: $36.41 | $0.00 |
DisclosureSEC source: 0001437749-17-013390 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 741 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning on December 11, 2013. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 741 | $73.84 | $54,715.07 |
DisclosureSEC source: 0001437749-17-013390 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F2 · price: Reflects the weighted average price of 741 shares of common stock of Proto Labs, Inc. sold by the reporting person on July 27, 2017 with sale prices ranging from $73.65 to $73.90 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:16 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 741 | $36.41 | $26,979.81 |
DisclosureSEC source: 0001437749-17-013390 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 20:03 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,259 | $0.00 Strike: $36.41 | $0.00 |
DisclosureSEC source: 0001437749-17-012933 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,741 Underlying: Common Stock · 3,259 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning on December 11, 2013. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 20:03 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 3,259 | $72.02 | $234,710.90 |
DisclosureSEC source: 0001437749-17-012933 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F2 · price: Reflects the weighted average price of 3,259 shares of common stock of Proto Labs, Inc. sold by the reporting person on July 19, 2017 with sale prices ranging from $72.00 to $72.10 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 20:03 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 3,259 | $36.41 | $118,660.19 |
DisclosureSEC source: 0001437749-17-012933 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:30 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $36.41 | $0.00 |
DisclosureSEC source: 0001437749-17-011139 · rdgdoc.xml · derivative · entry 3 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning in December 11, 2013. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:30 UTC | Proto Labs Inc PRLB · Entity 4553 | SaleCommon Stock | 4,000 | $66.01 | $264,032.80 |
DisclosureSEC source: 0001437749-17-011139 · rdgdoc.xml · nonDerivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,578 F2 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F3 · price: Reflects the weighted average price of 4,000 shares of common stock of Proto Labs, Inc. sold by the reporting person on June 8, 2017, with sale prices ranging from $66.00 to $66.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:30 UTC | Proto Labs Inc PRLB · Entity 4553 | Exercise / conversionCommon Stock | 4,000 | $36.41 | $145,640.00 |
DisclosureSEC source: 0001437749-17-011139 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reports the total number of shares of Common Stock of the issuer held by the reporting person as of June 12, 2017, including a total of 508 shares of Common Stock of the issuer purchased by the reporting person through the issuer's Employee Stock Purchase Plan program on May 15, 2014, November 15, 2014, and May 15, 2015. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:02 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 4,535 | $0.00 Strike: $58.35 | $0.00 |
DisclosureSEC source: 0001437749-17-002569 · rdgdoc.xml · derivative · entry 2 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,535 Underlying: Common Stock · 4,535 shares Expires 2027-02-13 F3 · derivative.exercise_date: The option vests as to 20% of the shares in five annual installments beginning on February 13, 2018. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:02 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 6,430 | $58.35 | $375,190.50 |
DisclosureSEC source: 0001437749-17-002569 · rdgdoc.xml · nonDerivative · entry 1 Bodor Robert · CIK 0001581088 · VP/General Manager-Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,070 F1 · shares: The restricted stock units vest as to 20% of the shares in five annual installments beginning on February 13, 2018. F2 · balance_after: Reports the total number of shares of Common Stock of the issuer held by the reporting person as of February 15, 2017, including 200 shares purchased on May 16, 2016 and 237 shares purchased on November 15, 2016 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.